AUTOIMMUNITY part 66

Immune 4

 

ANTICYTOKINE AGENTS

The development of TNF-α inhibitors in 1990s ushered in a new era of therapy of autoimmune disease using “biologicals” capable of interfering with the interactions between cytokines and their receptors. The initial clinical use of TNF inhibitors such as etanercept (a soluble recombinant TNF receptor II linked to the Fc portion of human IgG1), infliximab (a chimeric human-mouse anti-TNF-α monoclonal antibody), and adalimumab (a fully humanized monoclonal antibody against TNF-α) in RA demonstrated that although multiple cytokines may be involved in disease pathogenesis (in RA, IL-1 and IL-6 in addition to TNF-α), inhibitors of a single cytokine pathway may show therapeutic efficacy. In addition to RA, TNF-α inhibitors are used for treating  inflammatory bowel disease, psoriasis, and psoriatic arthritis and are being tested in sarcoidosis, Wegener’s granulomatosis, pyoderma gangrenosum, SLE and Behcet’s syndrome

Advertisements

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s